Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.34 is 57% above its 5-year average of -0.80, near the high end of its 5-year range (-1.81–-0.29).
10.53% above its 12-month average of -0.38.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.11.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 31 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.34
EARNINGS PER SHARE (EPS) AVG TTM
-0.38
EARNINGS PER SHARE (EPS) AVG 3Y
-0.38
EARNINGS PER SHARE (EPS) AVG 5Y
-0.80
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.53%
CURRENT VS 3Y AVG
+9.33%
CURRENT VS 5Y AVG
+57.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Trevi Therapeutics, Inc.
Market Cap
$1.87B
Earnings Per Share (EPS)
-0.34
TTM Avg
-0.38
3Y Avg
-0.38
5Y Avg
-0.80
Market Cap
$1.86B
Earnings Per Share (EPS)
-1.52
TTM Avg
0.75
3Y Avg
-3.08
5Y Avg
-7.20
Market Cap
$1.89B
Earnings Per Share (EPS)
1.02
TTM Avg
-0.34
3Y Avg
-1.38
5Y Avg
-0.96
Market Cap
$1.89B
Earnings Per Share (EPS)
-2.02
TTM Avg
-1.35
3Y Avg
-0.63
5Y Avg
-1.69
Market Cap
$1.89B
Earnings Per Share (EPS)
-7.01
TTM Avg
2.37
3Y Avg
-1.46
5Y Avg
-2.11
Market Cap
$1.85B
Earnings Per Share (EPS)
-2.54
TTM Avg
-3.71
3Y Avg
-3.97
5Y Avg
-3.29
Market Cap
$1.84B
Earnings Per Share (EPS)
-4.83
TTM Avg
-5.77
3Y Avg
-6.60
5Y Avg
-16.62
Market Cap
$1.83B
Earnings Per Share (EPS)
0.82
TTM Avg
0.69
3Y Avg
0.92
5Y Avg
1.05
Market Cap
$1.83B
Earnings Per Share (EPS)
N/A
TTM Avg
-2.33
3Y Avg
-4.62
5Y Avg
-5.13
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | $1.87B | -0.34 | -0.38 | -0.38 | -0.80 |
| Novavax, Inc. (NVAX)vs › | $1.86B | -1.52 | 0.75 | -3.08 | -7.20 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 1.02 | -0.34 | -1.38 | -0.96 |
| Zymeworks Inc. (ZYME)vs › | $1.89B | -2.02 | -1.35 | -0.63 | -1.69 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | -7.01 | 2.37 | -1.46 | -2.11 |
| Immunome, Inc. (IMNM)vs › | $1.85B | -2.54 | -3.71 | -3.97 | -3.29 |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | -4.83 | -5.77 | -6.60 | -16.62 |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 0.82 | 0.69 | 0.92 | 1.05 |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | N/A | -2.33 | -4.62 | -5.13 |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | -1.31 | -2.36 | -2.72 | -2.37 |
Trailing EPS (TTM)
$-0.34
Forward EPS (Est.)
$-0.48
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.29 |
| 2024-12-31 | -0.47 |
| 2023-12-31 | -0.29 |
| 2022-12-31 | -0.45 |
| 2021-12-31 | -1.49 |
| 2020-12-31 | -1.81 |
| 2019-12-31 | -1.46 |
| 2018-12-31 | -2.29 |
| 2017-12-31 | -1.43 |
| 2016-12-31 | -0.69 |
